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ABSTRACT Current guidelines suggest treating cancer patients with incidental pulmonary embolism
comparably to patients with symptomatic pulmonary embolism.
We used the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry to compare the
rate of major bleeding and symptomatic pulmonary embolism during the course of anticoagulation and
after its discontinuation in cancer patients with incidental pulmonary embolism.
As of March 2016, 715 cancer patients with incidental pulmonary embolism had been enrolled in RIETE.
During the course of anticoagulant therapy (mean 235 days), the rate of major bleeding was higher than
the rate of symptomatic pulmonary embolism (10.1 (95% CI 7.48–13.4) versus 3.17 (95% CI 1.80–5.19)
events per 100 patient–years, respectively), and the rate of fatal bleeding was higher than the rate of fatal
pulmonary embolism (2.66 (95% CI 1.44–4.52) versus 0.66 (95% CI 0.17–1.81) deaths per 100 patient-years,
respectively). After discontinuing anticoagulation (mean follow-up 117 days), the rate of major bleeding
was lower than the rate of symptomatic pulmonary embolism (3.00 (95% CI 1.10–6.65) versus 8.37 (95% CI
4.76–13.7) events per 100 patient-years, respectively); however, there were no differences in the rate of fatal
events at one death each.
The risk/benefit ratio of anticoagulant therapy in cancer patients with incidental pulmonary embolism
is uncertain and must be evaluated in further studies.
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Patients with active cancer frequently undergo routine imaging studies, which usually include chest
computed tomography (CT) scans, to assess the extent of the malignancy, the response to cancer therapy
or to screen for metastases. With the widespread use of CT testing, the detection of incidental pulmonary
embolism has become increasingly common [1, 2]. Current guidelines on antithrombotic therapy from the
American College of Chest Physicians (ACCP) and the American Society of Clinical Oncology (ASCO)
suggest treating patients with incidental pulmonary embolism as comparable patients with symptomatic
pulmonary embolism [3, 4]. However, supporting evidence for this recommendation is limited by the
small size of the studies [5–14]. Recently, VAN DER HULLE et al. [15] evaluated the outcome in 926 cancer
patients with incidental pulmonary embolism from 11 cohorts, and found that they had a high risk of
symptomatic pulmonary embolism events, particularly when left untreated. These findings may support
the guidelines’ recommendations. However, the follow-up period was limited to only 6 months, and there
was no information on the quality of anticoagulation, the consequences of pulmonary embolism or
bleeding events or the outcome after discontinuing anticoagulant therapy.
The Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry is an ongoing, multicentre,
international (Spain, Belgium, Canada, Czech Republic, Ecuador, France, Greece, Israel, Italy, Latvia,
Portugal, Republic of Macedonia and Switzerland) observational registry of consecutive patients with
objectively confirmed acute venous thromboembolism (VTE). Data from this registry have been used to
evaluate outcomes after acute VTE, such as the frequency of recurrent VTE, bleeding and mortality and
risk factors for these outcomes [16–19]. The aim of the current study was to compare the rate of
symptomatic VTE and major bleeding events appearing during the course of anticoagulant therapy and
after its discontinuation in patients with active cancer and incidental pulmonary embolism.
Patients and methods
Inclusion criteria
Consecutive patients with incidental pulmonary embolism at helical CT scan were enrolled in RIETE. All
patients provided written or oral consent for participation in the registry, in accordance with local ethics
committee requirements. This analysis was approved by the Ethics Committees of the UZ Gasthuisberg Hospital
in Leuven, Belgium (B70721111790) and the Hospital Clinic of Barcelona, Spain (Reg. HCB/2015/0386).
Physicians participating in the RIETE registry made all efforts to enrol consecutive patients. Data were
recorded on to a computer-based case report form at each participating hospital and submitted to a centralised
coordinating centre through a secure website. The coordinating centre assigned patients with a unique
identification number to maintain patient confidentiality and was responsible for all data management.
Study design
For this study, only patients with active cancer diagnosed with incidental pulmonary embolism were
considered. Active cancer was defined as newly (<3 months before) diagnosed cancer, metastatic cancer or
cancer that was being treated (i.e. surgery, chemotherapy, radiotherapy, support therapy or combined
therapies). Incidental pulmonary embolism was defined as pulmonary embolism detected on a CT scan
ordered for reasons other than a clinical suspicion of pulmonary embolism [20]. We compared their
clinical characteristics, chest CT scan findings, treatment and outcome during the course of anticoagulant
therapy and after its discontinuation according to the presence or absence of metastases. CT scan findings
were classified as centrally located thrombi (defined as a central or lobar thrombus location) and more
peripherally located thrombi (defined as a segmental or sub-segmental thrombus location).
The major outcome was the rate of symptomatic, objectively confirmed pulmonary embolism and major
bleeding occurring during the course of anticoagulation and after its discontinuation. Bleeding complications
were classified as “major” if they were overt and required a transfusion of two units of blood or more, or were
retroperitoneal, spinal or intracranial, or when they were fatal. Secondary outcomes were acute deep vein
thrombosis (DVT) minor bleeding, fatal pulmonary embolism and fatal bleeding. Each episode of clinically
suspected pulmonary embolism or DVT was investigated by ultrasonography, contrast venography, lung
scanning, helical CT scan or pulmonary angiography as appropriate. Minor bleeding was defined as any overt
bleed requiring medical assistance but not filling the criteria for major bleeding. Fatal pulmonary embolism,
in the absence of autopsy, was defined as any death appearing within 10 days after symptomatic pulmonary
embolism diagnosis, in the absence of any alternative cause of death. Fatal bleeding was defined as any death
occurring within 10 days of a major bleeding episode, in the absence of an alternative cause of death.
Baseline variables
The following parameters are routinely recorded in RIETE: patient’s baseline characteristics; clinical status
including any coexisting or underlying conditions; risk factors for VTE; laboratory data; treatment received
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upon VTE diagnosis (drugs, doses and duration); and the outcome during the course of anticoagulant
therapy. Immobilised patients were defined as non-surgical patients who had been immobilised (i.e., total
bed rest with bathroom privileges) for ⩾4 days in the 2-month period prior to VTE diagnosis. Surgical
patients were defined as those who underwent a surgical intervention in the 2 months prior to VTE.
Recent bleeding was defined as a major bleeding episode <30 days prior to VTE.
Treatment and follow-up
Patients were managed according to the clinical practice of each participating hospital (i.e., there was no
standardisation of treatment). Patients were followed-up for at least 3 months in the outpatient clinic.
During each visit, any signs or symptoms suggesting symptomatic VTE recurrences or bleeding
complications were noted. Each episode of clinically suspected recurrent VTE was investigated by repeat
compression ultrasonography, lung scanning, helical CT scan or pulmonary angiography as appropriate.
Most outcomes were classified as reported by the clinical centres. However, if staff at the coordinating
centre were uncertain how to classify a reported outcome, that event was reviewed by a central
adjudicating committee (less than 10% of events).
Data collection and monitoring
The primary investigator ensured a consecutive enrolment of qualified patients. The data collected were
recorded electronically using the RIETE report form accessible to each of the participating hospitals and
medical offices and were submitted securely to the central coordinating centre. Data were encrypted to ensure
confidentiality and security and patients were assigned a unique number by the study’s coordinating centre.
Quality measures were utilised regularly and electronically documented to expose errors or inconsistencies.
Statistical analysis
We used a t-tests and the Chi-squared test (or Fisher’s exact test where appropriate) to compare
continuous or categorical variables. Then, we carried out a multivariable analysis through a logistic
regression model trying to identify independent predictors for major bleeding and for symptomatic
pulmonary embolism during the course of anticoagulant therapy or after its discontinuation. Covariates
entering in the model were selected by a significance level of p<0.10 on univariable analysis, or by a well–
known association reported in the literature. SPSS software (version 20, SPSS Inc. Chicago, IL, USA) was
used for the statistical management of the data, and a two-sided p<0.05 was considered to be statistically
significant.
Results
As of March 2016, 715 patients with active cancer and incidental pulmonary embolism had been enrolled
in RIETE. Of these, 451 (63%) had metastatic cancer. Patients with metastases were significantly younger
and less likely to have recent surgery but more likely to have anaemia or thrombocytosis than those
without metastases (table 1). There were no differences in heart rate, respiratory rate or blood gases
between both subgroups or in the proportion of patients with peripheral (versus central) arteries involved
on CT scan. As to the site of cancer, patients with metastases were more likely to have lung or breast
cancer and less likely to have bladder or cerebral cancer (table 2). Most patients (98%) were initially
treated with low-molecular-weight heparin (LMWH), with similar doses between both subgroups. Then,
617 (86%) received long-term LMWH therapy, 63 (8.8%) switched to vitamin K antagonists and eight
(1.1%) received other drugs. Patients with metastatic cancer most likely received long-term therapy with
LMWH than those without metastases (OR 4.14; 95% CI 2.63–6.50).
Outcome during the course of anticoagulant therapy
During the course of anticoagulation (mean 235 days), 14 patients presented with symptomatic pulmonary
embolism (three died of the pulmonary embolism), six with DVT, 45 had major bleeding (12 died of
bleeding, eight bled in the brain), 32 had non-major, clinically relevant bleeding and 197 died (table 3).
The rate of major bleeding was three-fold higher than the rate of symptomatic pulmonary embolism (10.1
(95% CI 7.48–13.4) versus 3.17 (95% CI 1.80–5.19) events per 100 patient–years, respectively) (figure 1
and table 4). Moreover, the rate of non-major bleeding was five-fold higher than the rate of symptomatic
DVT (7.52 (95% CI 4.48–11.3) versus 1.34 (95% CI 0.54–2.78) events per 100 patient–years, respectively),
and the rate of fatal bleeding was four-fold higher than the rate of fatal pulmonary embolism (2.66 (95%
CI 1.44–4.52) versus 0.66 (95% CI 0.17–1.81) deaths per 100 patient-years, respectively). Patients with
metastatic cancer had a higher rate of major (OR 2.84; 95% CI 1.41–6.24) and fatal (OR 7.72; 95% CI
1.32–16.8) bleeding than those without metastases, with no differences in the rate of VTE or non-major
bleeding events. Pulmonary embolism was the eight most common cause of death (table 3).
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Outcome in the absence of anticoagulant therapy
The clinical outcome without anticoagulation was available for 229 patients: 13 did not receive
anticoagulant therapy at all and 216 were followed-up after discontinuing therapy. Of these, 136 (59%) had
metastases. During a mean follow-up of 117 days, 14 patients presented with symptomatic pulmonary
embolism, 13 with DVT, five had major bleeding, four had non-major bleeding and 84 died (table 5). The
rate of major bleeding was three-fold lower than the rate of symptomatic pulmonary embolism (3.00 (95%
CI 1.10–6.65) versus 8.37 (95% CI 4.76–13.7) events per 100 patient–years, respectively), and the rate of
non-major bleeding was also three-fold lower than the rate of DVT (2.40 (95% CI 0.76–5.78) versus
7.17 (95% CI 3.89–12.2) events per 100 patient–years, respectively). However, there was one fatal
pulmonary embolism and one fatal bleeding. The rate of symptomatic pulmonary embolism was five-fold
higher in patients with metastases than in those without (OR 5.13; 95% CI 1.30–33.8), with no differences
in the rate of DVT or bleeding events.
On multivariable analysis, patients with severe renal insufficiency (HR 3.61; 95% CI 1.14–11.5), leukocyte count
>11000 cells·µL−1 (HR 3.03; 95% CI 1.55–5.93), metastatic cancer (HR 3.03; 95% CI 1.55–5.93), ovarian cancer
(HR 5.38; 95% CI 1.69–17.1) or renal cancer (HR 4.23; 95% CI 1.24–14.4) were at increased risk for major
bleeding (table 6). Those with colorectal cancer were at lower risk for symptomatic pulmonary embolism.
Discussion
Current guidelines on antithrombotic therapy suggest treating cancer patients with incidental pulmonary
embolism as similar patients with symptomatic pulmonary embolism [3, 4]. In our cohort, the rate of major
bleeding during the course of anticoagulant therapy was three-fold higher than the rate of symptomatic
TABLE 1 Clinical characteristics in 715 cancer patients with incidental pulmonary embolism,
according to the presence or absence of metastases
Metastases No metastases OR (95% CI) or p-value
Patients n 451 264
Clinical characteristics
Age years 65±11 70±11
Male 268 (59) 165 (63) 0.88 (0.64–1.20)
Body weight kg 71±12 74±15
Additional risk factors for VTE
Surgery 44 (9.8) 40 (15) 0.61 (0.38–0.96)
Immobility ⩾4 days 65 (14) 39 (15) 0.97 (0.63–1.49)
Oestrogen therapy 24 (5.3) 11 (4.2) 1.29 (0.62–2.68)
None of the above 322 (71) 179 (68) 1.19 (0.85–1.65)
Prior VTE 31 (6.9) 21 (8.0) 0.85 (0.48–1.52)
Comorbidities
Chronic lung disease 49 (11) 29 (11) 0.99 (0.61–1.61)
Chronic heart failure 19 (4.2) 13 (4.9) 0.85 (0.41–1.75)
Creatinine clearance 30–60 mL·min−1 94 (21) 66 (25) 0.79 (0.55–1.13)
Creatinine clearance <30 mL·min−1 8 (1.8) 8 (3.0) 0.58 (0.21–1.56)
Recent major bleeding 13 (2.9) 14 (5.3) 0.53 (0.25–1.15)
Anaemia 294 (65) 143 (54) 1.58 (1.16–2.16)
WBC >11000 cells·μL−1 87 (19) 47 (18) 1.10 (0.75–1.63)
Platelet count <100000 per μL 16 (3.5) 8 (3.0) 1.18 (0.50–2.79)
Platelet count >450000 per μL 34 (7.5) 10 (3.8) 2.07 (1.01–4.26)
Respiratory tests
Respiratory rate breaths·min−1 (n=358) 18±3 17±6 0.326
Respiratory rate >20 breaths·min−1 22 (9.0) 12 (11) 0.83 (0.40–1.74)
Heart rate beats·min−1 (n=633) 82±15 84±19 0.168
Heart rate >110 beats·min−1 20 (5.0) 20 (8.7) 0.55 (0.29–1.05)
Oxygen saturation % (n=197) 95±7 94±6 0.581
Oxygen saturation <90% 7 (6.1) 6 (7.2) 0.84 (0.27–2.60)
Chest CT findings
Largest arteries involved
Segmental or subsegmental 123 (27) 84 (32) 0.80 (0.58–1.12)
Pulmonary or lobar 266 (59) 129 (49) 1.50 (1.11–2.04)
Not reported 62 (14) 51 (19) 0.67 (0.44–1.00)
Data are presented as mean±SD or n (%), unless otherwise stated. VTE: venous thromboembolism; WBC:
white blood cell count; CT: computed tomography.
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pulmonary embolism (45 versus 14 events, respectively), the rate of non-major bleeding was five-fold higher
than the rate of symptomatic DVT (32 versus six events, respectively) and the rate of fatal bleeding was
four-fold higher than the rate of fatal pulmonary embolism (12 versus three deaths, respectively). After
discontinuing anticoagulant therapy, the rate of major bleeding was three-fold lower than the rate of
symptomatic pulmonary embolism (five versus 14 events, respectively), the rate of non-major bleeding was
also three-fold lower than the rate of symptomatic DVT (four versus 12 events, respectively) and the rate of
fatal bleeding was similar to the rate of fatal pulmonary embolism (one death each).
We identified patients at high risk for major bleeding (those with renal insufficiency, anaemia, leukocytosis
or metastases), but failed to identify those at high risk for symptomatic pulmonary embolism (only
patients with colorectal cancer were found to be at increased risk). Thus, we can only state that the risk/
benefit ratio of anticoagulant therapy in cancer patients with incidentally found pulmonary embolism is
uncertain and must be evaluated in further studies.
Our data disagree with those from a recent study using individual patient data from studies identified by a
systematic literature search [15]. In 926 cancer patients with incidental pulmonary embolism from 11
cohorts in different countries, weighted pooled 6-month rates of recurrent VTE (including both DVT and
pulmonary embolism) and major bleeding were similar. This notable difference with our data may be likely
explained by differences in clinical characteristics, quality of anticoagulation or duration of anticoagulant
therapy. Unfortunately however, this information was unavailable in the study by VAN DER HULLE et al. [15].
There was no information either on the clinical consequences of symptomatic pulmonary embolism or
bleeding (particularly mortality) nor on the outcome after discontinuing anticoagulant therapy.
TABLE 2 Sites of cancer and treatment according to the presence or absence of metastases
Metastases No metastases OR (95% CI) or p-value
Patients n 451 264
Site of cancer
Colorectal 89 (20) 67 (25) 0.72 (0.50–1.04)
Lung 114 (25) 33 (13) 2.37 (1.55–3.61)
Breast 41 (9.1) 13 (4.9) 1.93 (1.01–3.67)
Gastric 31 (6.9) 15 (5.7) 1.23 (0.65–2.31)
Pancreas 29 (6.4) 10 (3.8) 1.75 (0.84–3.64)
Kidney 21 (4.7) 13 (4.9) 0.94 (0.46–1.92)
Bladder 13 (2.9) 20 (7.6) 0.36 (0.18–0.74)
Ovary 16 (3.5) 7 (2.7) 1.35 (0.55–3.33)
Prostate 15 (3.3) 8 (3.0) 1.10 (0.46–2.63)
Melanoma 19 (4.2) 2 (0.76) 5.76 (1.33–24.9)
Uterus 9 (2.0) 6 (2.3) 0.88 (0.31–2.49)
Oesophagus 10 (2.2) 4 (1.5) 1.47 (0.46–4.75)
Cerebral 4 (0.89) 9 (3.4) 0.25 (0.08–0.83)
Other 40 (8.0) 57 (16) 0.35 (0.23–0.55)
Initial therapy
LMWH 433 (96) 246 (93) 1.76 (0.90–3.45)
Mean LMWH doses IU·kg−1·day−1 163±42 165±43 0.496
Unfractionated heparin 6 (1.3) 11 (4.2) 0.31 (0.11–0.85)
Other 3 (0.67) 3 (1.1) 0.58 (0.12–2.91)
No anticoagulant therapy 9 (2.0) 4 (1.5) 1.32 (0.40–4.34)
Vena cava filter 9 (2.0) 19 (7.2) 0.26 (0.12–0.59)
Long-term therapy
Vitamin K antagonists 11 (2.4) 52 (20) 0.10 (0.05–0.20)
LMWH 418 (93) 199 (75) 4.14 (2.63–6.50)
Mean LMWH doses IU·kg−1·day−1 150±39 144±41 0.097
LMWH doses >150 IU·kg−1·day−1 213 (51) 85 (43) 1.39 (0.98–1.96)
Other 5 (1.1) 3 (1.1) 0.98 (0.23–4.11)
No anticoagulant therapy 17 (3.8) 10 (3.8) 0.99 (0.45–2.21)
Cancer therapy
Chemotherapy 278 (62) 88 (33) 3.21 (2.34–4.42)
Radiotherapy 46 (10) 22 (8.3) 1.25 (0.73–2.13)
Hormonal therapy 27 (6.0) 15 (5.7) 1.06 (0.55–2.03)
Data are presented as n (%) or mean±SD, unless otherwise stated. LMWH: low-molecular-weight heparin.
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The present study however, has potential limitations. Firstly, since RIETE is an observational registry (and
not a randomised trial) our data are hypothesis-generating. They might be a useful basis for future
controlled clinical trials comparing different therapeutic strategies, but we should be extremely cautious in
suggesting changes in treatment strategies just because of uncontrolled registry data. Secondly, patients were
not treated with a standardised anticoagulant regimen; treatment varied with local practice, and is likely to
have been influenced by a physician’s assessment of a patient’s risk of bleeding. Thirdly, to fulfil the
definition of fatal pulmonary embolism, it is mandatory in RIETE that patients must first experience an
TABLE 3 Clinical outcome during the course of anticoagulation (patients not receiving anticoagulation were not considered)
Metastases No metastases HR (95%CI)
or p-value
n Events per
100 patient-years (95% CI)
n Events per
100 patient-years (95% CI)
Patients n 442 245
Duration of therapy days mean±SD 218±248 261±292
Duration days median (interquartile range) 142 (94–268) 186 (99–322)
Duration n (%)
<3 months 97 (22) 38 (14) 0.023
3–6 months 175 (39) 88 (33) 0.149
>6 months 173 (38) 135 (51) 0.001
Symptomatic pulmonary embolism 9 3.43 (1.67–6.29) 5 2.79 (1.02–6.19) 1.23 (0.41–4.04)
Recurrent deep vein thrombosis 5 1.91 (0.70–4.23) 1 0.54 (0.03–2.65) 3.55 (0.49–84.5)
Major bleeding 36 13.9 (9.85–19.0) 9 4.88 (2.38–8.95) 2.84 (1.41–6.24)
Sites of major bleeding
Gastrointestinal 12 4.52 (2.45–7.69) 3 1.62 (0.41–4.40) 2.80 (0.84–12.4)
Cerebral 6 2.26 (0.92–4.70) 2 1.08 (0.18–3.56) 2.10 (0.44–15.1)
Urinary 7 2.64 (1.16–5.23) 0
Retroperitoneal 2 0.75 (0.13–2.49) 1 0.54 (0.03–2.65) 1.40 (0.11–41.3)
Non-major bleeding 21 8.08 (5.13–12.1) 11 6.29 (3.31–10.9) 1.28 (0.62–2.76)
Urinary 5 1.89 (0.69–4.20) 4 2.16 (0.69–5.22) 0.88 (0.22–3.66)
Gastrointestinal 6 2.27 (0.92–4.72) 0
Haematoma 1 0.38 (0.02–1.86) 5 2.72 (1.00–6.03) 0.14 (0.01–1.00)
Overall mortality 161 60.6 (51.8–70.6) 36 19.3 (13.7–26.5) 3.14 (2.21–4.56)
Causes of death
Disseminated malignancy 120 45.2 (37.6–53.8) 24 12.9 (8.45–18.9) 3.51 (2.29–5.54)
Bleeding 11 4.14 (2.18–7.20) 1 0.54 (0.03–2.65) 7.72 (1.32–16.8)
Infection 9 3.39 (1.65–6.22) 3 1.61 (0.41–4.38) 2.10 (0.59–9.64)
Respiratory insufficiency 2 0.75 (0.13–2.49) 2 1.07 (0.18–3.55) 0.70 (0.07–6.74)
Multi-organ failure 2 0.75 (0.13–2.49) 2 1.07 (0.18–3.55) 0.70 (0.07–6.74)
Bowel occlusion 4 1.51 (0.48–3.63) 0
Liver insufficiency 4 1.51 (0.48–3.63) 0
Pulmonary embolism 3 1.13 (0.29–3.08) 0
Other 6 2.26 (0.92–4.70 4 2.16 (0.69–5.22) 1.03 (0.44–3.14)
FIGURE 1 Cumulative rates of major
bleeding and symptomatic
pulmonary embolism (PE) events
appearing during the course of
anticoagulant therapy, according to
the presence or absence of
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objectively confirmed pulmonary embolism event followed by death within the first 10 days. Thus, all
sudden unexplained deaths which are usually considered as “likely” fatal pulmonary embolism in many
randomised trials are not considered in this analysis, and our study may have underestimated some patients
who may have died of pulmonary embolism, especially after hospital discharge. However, a sudden death
may also be due to a cerebral bleeding. Finally, patients in the RIETE database were selected in several
different countries. The variability of practices in different countries could potentially affect the study
outcomes. For instance, the dosing and timing of pharmacological treatment can vary according to each
individual’s country’s pattern of practice, underlying disease process and/or presence or absence of a
diagnosed malignancy. Furthermore, a variety of practitioners entered data into the registry, which may lend
itself to potential inaccuracies in the data being reported. The main strengths of our observation are the high
TABLE 4 Cumulative rates of major bleeding and symptomatic pulmonary embolism events
appearing during the course of anticoagulant therapy, according to the presence or absence of
metastases (first 12 months)
Day
7 30 90 180 360
Patients at risk
Metastases 442 426 379 259 124
No metastases 260 253 236 177 96
Major bleeding
Metastases 6 (1.35) 11 (2.52) 17 (4.02) 30 (8.81) 33 (10.9)
No metastases 1 (0.39) 4 (1.58) 6 (2.4) 7 (3) 8 (3.88)
Symptomatic pulmonary embolism
Metastases 0 2 (0.48) 4 (1) 4 (1) 6 (2.42)
No metastases 0 0 3 (1.27) 3 (1.27) 4 (2.45)
Data are presented as n or n (%).
TABLE 5 Clinical outcome after discontinuing anticoagulant therapy (patients not receiving anticoagulation are also included)
Metastases No metastases Hazard ratio
(95% CI) or p-value
n Events per
100 patient-years (95% CI)
n Events per
100 patient-years (95% CI)
Patients n 136 93
Duration of therapy days mean±SD 242±310 303±395
Duration days median (interquartile range) 134 (47–302) 155 (45–463)
Duration n (%)
<3 months 49 (36) 37 (40) 0.581
3–6 months 32 (24) 12 (13) 0.060
>6 months 55 (40) 44 (47) 0.342
Symptomatic pulmonary embolism 12 13.3 (7.21–22.6) 2 2.60 (0.44–8.57) 5.13 (1.30–33.8)
Recurrent deep vein thrombosis 9 9.97 (4.86–18.3) 3 3.89 (0.99–10.6) 2.56 (0.72–11.7)
Major bleeding 3 3.34 (0.85–9.10) 2 2.60 (0.44–8.59) 1.29 (0.19–10.8)
Sites of major bleeding
Gastrointestinal 3 3.34 (0.85–9.10) 1 1.30 (0.07–6.41) 2.57 (0.27–67.7)
Retroperitoneal 0 1 1.30 (0.06–6.40)
Non-major bleeding 2 2.22 (0.37–7.35) 2 2.60 (0.44–8.58) 0.86 (0.09–8.22)
Death 68 75.3 (58.9–94.9) 16 20.8 (12.3–33.0) 3.63 (2.14–6.44)
Causes of death
Disseminated malignancy 53 58.7 (44.4–76.2) 9 11.7 (5.70–21.4) 5.03 (2.57–10.8)
Infection 2 2.22 (0.37–7.32) 1 1.30 (0.06–6.40) 1.71 (0.13–50.3)
Respiratory insufficiency 3 3.32 (0.85–9.04) 0
Ischaemic stroke 1 1.11 (0.06–5.46) 1 1.30 (0.06–6.40) 0.85 (0.02–33.3)
Liver insufficiency 1 1.11 (0.06–5.46) 1 1.30 (0.06–6.40) 0.85 (0.02–33.3)
Pulmonary embolism 1 1.11 (0.06–5.46) 0
Bleeding 0 1 1.30 (0.06–6.40)
Multi-organ failure 0 1 1.30 (0.06–6.40)
Unknown 3 3.32 (0.85–9.04) 2 2.60 (0.44–8.57) 1.28 (0.19–10.8)
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number of included patients, the strict and identical diagnostic criteria for incidental pulmonary embolism
and the reporting of objectively established outcomes (major bleeding and symptomatic pulmonary
embolism). Additionally, the population-based sample we used describes the effects of anticoagulant therapy
in “real world” clinical care, as opposed to in a protocol driven randomised trial, and enhances the
generalisability of our findings.
In summary, cancer patients with incidental pulmonary embolism have a high risk for recurrent pulmonary
embolism if they do not receive anticoagulant therapy, but have a high risk for bleeding complications as
well during the course of anticoagulation. Hence, the risk/benefit ratio of anticoagulation is uncertain and
must be evaluated in further studies.
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TABLE 6 Multivariable analysis for major bleeding and for symptomatic pulmonary embolism
Major bleeding Symptomatic
pulmonary embolism
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Underlying diseases
Creatinine clearance <30 mL·min−1 3.61 (1.14–11.5) 0.029
Anaemia 1.96 (0.98–2.55) 0.059
WBC >11000 cells·µL−1 3.03 (1.55–5.93) 0.001
Cancer characteristics
With metastases 2.35 (1.15–4.79) 0.019
Colorectal cancer 0.23 (0.06–0.90) 0.035
Ovarian cancer 5.38 (1.69–17.1) 0.004
Renal cancer 4.23 (1.24–14.4) 0.021
On anticoagulant therapy 7.69 (4.00–14.3) <0.001 0.23 (0.10–0.54) 0.001
WBC: white blood cell count.
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